Research and Markets: Growth Forecasts of the Functional Genomics Market to 2007.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c9455) has announced the addition of Functional Genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) : A Strategic Market Analysis to their offering. A comprehensive analysis on the area of Functional Genomics, focusing on the available technologies and applications of the Microarray Gene Expression Technologies, Non-array Gene Expression Technologies, Knockout and Transgenic Animals Transgenic animal Animals that have had genes from other species inserted into their genetic code. Mentioned in: Glycogen Storage Diseases and Downregulation Reagents market segments. Detailing the drivers, barriers and unmet needs impacting each market segment as well as the industry as a whole, this report provides growth forecasts through 2007 and recommends deal structures and identifies strategic growth opportunities for current participants and new entrants to this market. I. Executive Summary A Functional Genomics Overview B. Multiple Disciplines in Drug Discovery C. Applications of Functional Genomics D. Functional Genomics Technologies 1. Overview 2. Data Quality vs. Throughput E. Worldwide Market 1. Annual Worldwide Revenues (2002E-2007E) 2. Supplier Market Share 3. Market Share by Technology Segment 4. Segment Market Projections F. Factors Affecting Functional Genomics 1. Overview 2. Functional Genomics Market Drivers 3. Functional Genomics Market Bottlenecks G. Strategic Analysis 1. Overview 2. Near Term Industry Landscape 3. Leading Business Scenarios 4. Strategic Recommendations H. Market Attractiveness II. Objectives and Methodology A. Report Objective and Scope 1. Objectives 2. Scope B. Methodology 1. Functional Genomics Market Models 2. Model Assumptions C. Key Players and Strategic Analysis 1. Technology Assessment 2. Market Position D. Data Collection 1. Primary Sources a. Functional Genomics Thought Leaders b. Representative Questions 2. Secondary Sources E. Strategic Recommendation 1. Strategy Development 2. External Analysis 3. Segment Entry Analysis Methodology III. Functional Genomics Background A. Overview 1. Scientific Background 2. Historical Perspective B. Multiple Disciplines in Drug Discovery 1. Proteomics 2. Bioinformatics 3. SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily Analysis / Pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. 4. Cellular Assays 5. Structural Genomics Noun 1. structural genomics - the branch of genomics that determines the three-dimensional structures of proteins genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) 6. In Silico Methods C. Functional Genomics 1. Introduction 2. Applications of Functional Genomics 3. Technologies IV. The Functional Genomics Market IV-1 A. Worldwide Market IV-1 1. Annual Worldwide Revenue - 2002E to 2007E IV-1 2. Supplier Market Share - 2002E and 2007E IV-2 3. Market Share by Technology Segment - 2002E and 2007E IV-3 4. Segment Market Projections IV-4 B. Segment Market Projections IV-5 1. Microarray Gene Expression Technologies IV-5 a. Revenues - 2002E to 2007E IV-5 b. Segment Market Share - 2002E and 2007E IV-6 c. Supplier Market Shares - 2002E and 2007E IV-7 d. Supplier Competitive Analysis IV-8 i. Positional Evaluation Bubbles IV-8 (a) Comparison in 2002E IV-8 (b) Comparison in 2007E IV-10 ii. Affymetrix IV-12 iii. Agilent IV-14 iv. PerkinElmer IV-16 v. Apogent IV-18 e. Technical Benefits and Limitations IV-20 i. Increased Probe Labeling IV-21 ii. Scanning Technologies IV-22 iii. Costs IV-23 iv. Standardization of Array Technologies IV-24 f. Market Model Assumptions IV-25 2. Non-array Based Gene Expression Technologies Market IV-27 a. Revenues - 1998 to 2007E IV-27 b. Segment Market Shares - 2002E and 2007E IV-28 c. Supplier Market Shares - 2002E and 2007E IV-29 d. Supplier Competitive Analysis IV-30 i. Positional Evaluation Bubbles IV-30 (a) Comparison in 2002E IV-30 (b) Comparison in 2007E IV-32 ii. Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. IV-34 iii. Gene Logic IV-36 iv. Genzyme Molecular Oncology IV-38 v. Digital Gene Technologies IV-40 e. Technical Benefits and Limitations IV-42 i. Technology IV-43 ii. Microarray Validation IV-44 iii. Lower Throughput IV-45 f. Market Model Assumptions IV-46 3. Downregulation IV-49 a. Revenues - 2002E to 2007E IV-49 b. Segment Market Shares - 2002E and 2007E IV-50 c. Supplier Market Shares - 2002E and 2007E IV-51 d. Supplier Competitive Analysis IV-52 i. Positional Evaluation Bubbles IV-52 (a) Comparison in 2002E IV-52 (b) Comparison in 2007E IV-54 ii. Isis GeneTrove IV-56 iii. Immusol IV-58 iv. Sangamo Biosciences IV-60 v. Sequitur IV-62 e. Technical Benefits and Limitations IV-64 I. Other Applications IV-65 ii. Expertise Requirement IV-66 iii. Versatility IV-67 iv. Time Efficiency IV-68 f. Market Model Assumptions IV-69 4. Animal Models IV-71 a. Revenues - 2002E to 2007E IV-71 b. Segment Market Shares - 2002E and 2007E IV-72 c. Supplier Market Shares - 2002E and 2007E IV-73 d. Supplier Competitive Analysis IV-74 i. Positional Evaluation Bubbles IV-74 (a) Comparison in 2002E IV-74 (b) Comparison in 2007E IV-76 ii. Deltagen IV-78 iii. Exelixis IV-80 iv. Lexicon Genetics IV-82 e. Technical Benefits and Limitations IV-84 I. High Quality Information IV-85 ii. Low Throughput and High Cost IV-86 iii. Mutation of Developmental Genes IV-87 iv. Controlled Experiments IV-88 f. Market Model Assumptions IV-89 V. Functional Genomics Technologies A. Technology Overview B. Microarray Technologies 1. Description a. Probe Synthesis and Deposition b. Microarray Substrate Materials 2. Technologies a. cDNA Arrays b. Oligonucleotide Oligonucleotide A deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequence composed of two or more covalently linked nucleotides. Oligonucleotides are classified as deoxyribooligonucleotides or ribooligonucleotides. Arrays 3. Proof of Concept Examples a. Next Generation Atlas Array b. GeneChip Oligonucleotide Array 4. Expert Commentary C. Non-array Based Gene Expression Technologies 1. Description V-12 2. Technologies V-13 a. Total Gene Expression Analysis (TOGA toga Loose, draped outer garment adopted by the Romans from the Etruscans. It was originally worn by both sexes of all classes, but was gradually abandoned by women, then by labourers, and finally by patricians, but throughout the history of the empire it remained the state ) V-13 b. Serial Analysis of Gene Expression Serial analysis of gene expression (SAGE) is a technique used by molecular biologists to produce a snapshot of the messenger RNA population in a sample of interest. The original technique was developed by Dr. (SAGE) V-13 c. Restriction Enzyme restriction enzyme Protein (more specifically, an endonuclease) produced by bacteria that cleaves DNA at specific sites along its length. Thousands have been found, from many different bacteria; each recognizes a specific nucleotide sequence. Analysis of Differentially Expressed Sequences (READS) d. Realtime Polymerase Chain Reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ) V-16 3. Proof of Concept Examples a. TOGA Technology in Schizophrenia Research V-17 b. SAGE Technology in Non-small Cell Lung Cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. Research c. READS Technology in Cardiovascular Research V-19 d. Real Time PCR to Validate Microarray Results V-20 4. Expert Commentary V-21 D. Downregulation Technologies V-22 1. Description V-22 2. Technologies V-24 a. Ribozymes V-24 b. Antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). Oligonucleotides V-25 c. Zinc Fingers Proteins V-27 3. Proof of Concept Examples V-28 a. Ribozyme Ribozyme A ribonucleic acid (RNA) molecule that, like a protein, can catalyze specific biochemical reactions. Examples include self-splicing rRNA and RNase P, both involved in catalyzing RNA processing reactions (that is, the biochemical reactions that convert Technology as a Key Target Identification and Validation Tool V-28 b. Antisense Technology in Gene Studies V-29 c. Zinc Finger Protein A zinc finger protein is a DNA-binding protein domain comprised of zinc fingers ranging from two in the Drosophila regulator ADR1, the more common three in mammalian Sp1 up to nine in TFIIIA. Technology in Obesity Research V-30 4. Expert Commentary V-31 E. Animal Models V-32 1. Description V-32 2. Technologies V-37 a. Knockout Methods V-37 b. Transgenesis trans·gen·e·sis n. The transfer of cloned genetic material from one species or breed to another. transgenesis transfer of genes from one individual into the genome of another who transmits it to successive generations. V-38 3. Proof of Concept Examples V-39 a. Knockout Methods in Schizophrenia Research V-39 b. Transgenics trans·gen·ics n. (used with a sing. or pl. verb) The study of or methodology used to create transgenic animals or plants. in Neurological Disease Noun 1. neurological disease - a disorder of the nervous system nervous disorder, neurological disorder disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder"; Research V-40 4. Expert Commentary V-41 VI. Functional Genomics Drivers and Bottlenecks VI-1 A. Factors Affecting Functional Genomics VI-1 B. Functional Genomics Market Drivers VI-2 1. Need for More Drug Candidates VI-3 a. Product Pipeline VI-3 b. Patents VI-5 c. Competition VI-6 2. Need for Increased R&D Productivity VI-7 a. Application of Genetic Data VI-7 b. Reduction of Approval Time VI-8 c. Shorter Drug Discovery Period VI-9 3. Need for Eventual R&D Cost Reduction VI-10 a. Cutting Total Drug Development Costs VI-10 b. Decreasing Pre-clinical Development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. Costs VI-11 4. Improved Products VI-12 a. Reduced Drug Toxicity VI-12 b. Improved Drug Efficacy VI-13 C. Functional Genomics Market Bottlenecks VI-14 1. Cost Constraints VI-15 a. Capital Expenditures VI-15 b. Cost Justification VI-16 2. Technical Hurdles VI-17 a. Device Complications and Inaccuracy in·ac·cu·ra·cy n. pl. in·ac·cu·ra·cies 1. The quality or condition of being inaccurate. 2. An instance of being inaccurate; an error. VI-17 b. Technical Hurdle VI-18 3. Patent and Intellectual Property Issues VI-19 a. Functional Genomics: Invention vs. Discovery VI-19 b. Patent Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. VI-20 4. Government Regulation VI-21 a. Bioethics bioethics, in philosophy, a branch of ethics concerned with issues surrounding health care and the biological sciences. These issues include the morality of abortion, euthanasia, in vitro fertilization, and organ transplants (see transplantation, medical). VI-21 b. Tightening FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. Standards VI-22 VII. Strategic Analysis A. Overview B. Near Term Industry Landscape 1. Evolution and Rapid Adoption of Novel Technologies 2. Consolidation within the Functional Genomics Industry 3. Increased Regulatory Impact on Business and Technology C. Leading Business Scenarios 1. Fully Integrated Pharmaceutical Company 2. Reseller/Licensing Deals 3. Alliances 4. Mergers and Acquisitions D. Strategic Recommendations 1. Market Opportunities a. Satisfying Technical Unmet Needs b. Resolving Bottlenecks in Functional Genomics Market 2. Revenue Optimization a. Technology Partnerships b. Development Partnerships 3. Positioning for Future Success a. Expanding Proven Technologies b. Seizing Market Entry Opportunities Appendices Appendix A: Company Profiles A. Company Profiles Appendix B: Definitions and Acronyms A. Definitions B. Acronyms Appendices Appendix A: Company Profiles A. Company Profiles Appendix B: Definitions and Acronyms A. Definitions B. Acronyms For more information visit http://www.researchandmarkets.com/reports/c9455 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion